Inclusion Criteria:

          -  Biopsy proven (from primary lesion and/or lymph nodes) diagnosis of cancer of the
             nasopharynx

          -  Patients must have detectable pretreatment plasma EBV DNA, determined by the central
             lab prior to Step 2 registration

          -  Stage II-IVB disease (American Joint Committee on Cancer [AJCC], 7th edition [ed.])
             with no evidence of distant metastasis, based upon the following minimum diagnostic
             workup:

               -  History/physical examination by a Medical Oncologist or Clinical Oncologist or
                  Radiation Oncologist or Ear, Nose, Throat specialist (ENT), which must include an
                  endoscopic evaluation, a complete list of current medications, and assessment of
                  weight and weight loss in the past 6 months within 21 days prior to registration

               -  Evaluation of tumor extent with magnetic resonance imaging (MRI) of the
                  nasopharynx and neck within 28 days prior to registration; if MRI is medically
                  contraindicated, obtain computed tomography (CT) scan with =< 3 mm contiguous
                  slices with contrast and bone windows (to evaluate base of skull involvement);
                  Note: If a treatment planning CT scan is used, it must be with =< 3 mm contiguous
                  slices with contrast and be read by a radiologist

               -  To rule out distant metastasis, patients must undergo the following imaging
                  within 28 days prior to registration:

                    -  A CT scan with contrast of the chest, abdomen, and/or pelvis or a total body
                       positron emission tomography (PET)/CT scan (non-contrast PET/CT is
                       acceptable)

                    -  A bone scan only when there is suspicion of bone metastases (a PET/CT scan
                       can substitute for the bone scan)

          -  Zubrod performance status 0-1 within 21 days prior to registration

          -  Absolute neutrophil count (ANC) >= 1,500 cells/mm^3

          -  Platelets >= 100,000 cells/mm^3

          -  Hemoglobin >= 8.0 g/dl (Note: the use of transfusion or other intervention to achieve
             hemoglobin [Hgb] >= 8.0 g/dl is acceptable)

          -  Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 1.5 x
             institutional ULN

          -  Alkaline phosphatase =< 1.5 x institutional ULN

          -  Serum creatinine =< 1.5 mg/dl or calculated creatinine clearance (CC) >= 50 ml/min
             determined by 24-hour urine collection or estimated by Cockcroft-Gault formula

          -  Negative serum pregnancy test within 14 days prior to registration for women of
             childbearing potential

          -  Women of childbearing potential and male participants who are sexually active must
             agree to use a medically effective means of birth control throughout protocol
             treatment

          -  Patient must provide study specific informed consent prior to study entry, including
             the mandatory pre-treatment plasma EBV DNA assay

        Exclusion Criteria:

          -  Prior invasive malignancy (except node negative, non-melanomatous skin cancer) unless
             disease free for a minimum of 1095 days (3 years) (for example, carcinoma in situ of
             the breast, oral cavity, or cervix are all permissible)

          -  Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a
             different cancer is allowable; however, at least 6-weeks recovery is necessary if the
             last regimen included nitrosourea or mitomycin

          -  Prior radiotherapy to the region of the study cancer that would result in overlap of
             radiation therapy fields

          -  Patients with hearing loss assessed to be primarily sensorineural in nature, requiring
             a hearing aid, or intervention (i.e. interfering in a clinically significant way with
             activities of daily living); a conductive hearing loss that is tumor-related is
             allowed

          -  >= Grade 2 peripheral sensory neuropathy (CTCAE, v. 4.0)

          -  Severe, active co-morbidity, defined as follows:

               -  Major medical or psychiatric illness, which in the investigator's opinion would
                  interfere with the completion of therapy and follow up or with full understanding
                  of the risks and potential complications of the therapy

               -  Unstable angina and/or uncontrolled congestive heart failure within the past 6
                  months

               -  Myocardial infarction within the last 6 months

               -  Acute bacterial or fungal infection requiring intravenous antibiotics at the time
                  of registration; note that patients switched from IV antibiotics and currently on
                  oral antibiotics whose infection is assessed to be adequately treated or
                  controlled are eligible

               -  Chronic obstructive pulmonary disease exacerbation or other respiratory illness
                  requiring hospitalization or precluding study therapy within 30 days prior to
                  registration

               -  Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease
                  Control and Prevention (CDC) definition; note, however, that human
                  immunodeficiency virus (HIV) testing is not required for entry into this protocol

          -  Pregnancy or women of childbearing potential and men who are sexually active and not
             willing/able to use medically acceptable forms of contraception

          -  Prior allergic reaction to the study drug(s) involved in this protocol

          -  Patients with undetectable pre-treatment plasma EBV DNA